Literature DB >> 20083310

Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease.

Michael Maes1, Ivanka Mihaylova, Marta Kubera, Marc Uytterhoeven, Nicolas Vrydags, Eugene Bosmans.   

Abstract

BACKGROUND: Major depression is characterized by a decreased antioxidant status, an induction of the inflammatory and oxidative and nitrosative (IO&NS) pathways and inflammatory-neurodegenerative (I&ND) pathways. This study examines two markers of oxidative stress in depression, i.e. plasma peroxides and serum oxidized LDL (oxLDL) antibodies.
METHODS: Blood was sampled in 54 patients with major depression (mean+/-SD age=43.5+/-11.6 years) and 37 normal volunteers (43.6+/-11.1 years). The severity of illness was measured by means of the Hamilton Depression Rating Scale. The Fibromyalgia and Chronic Fatigue Syndrome Rating Scale was used to measure severity of "psychosomatic" symptoms in depression.
RESULTS: We found significantly higher plasma peroxides (p=0.002) and serum oxLDL antibodies (p=0.0002) in depressed patients as compared to normal controls. There was no significant correlation between both markers and both independently from each other predicted major depression. There were significant correlations between the oxLDL antibodies and the scores on two items of the FF scale, i.e. gastro-intestinal symptoms and headache. DISCUSSION: The results show that major depression is accompanied by increased oxidative stress and lipid peroxidation. These results further extend the IO&NS pathophysiology of major depression. Since increased peroxides and oxLDL antibodies are predictors of coronary artery disease (CAD) and neurodegeneration, our findings suggest that IO&NS pathways are involved in the increased incidence of both CAD and neurodegeneration in depression. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20083310     DOI: 10.1016/j.jad.2009.12.014

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  48 in total

Review 1.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

2.  Depression and oxidative stress: results from a meta-analysis of observational studies.

Authors:  Priya Palta; Laura J Samuel; Edgar R Miller; Sarah L Szanton
Journal:  Psychosom Med       Date:  2013-12-12       Impact factor: 4.312

Review 3.  Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.

Authors:  George Anderson; Michael Berk; Olivia Dean; Steven Moylan; Michael Maes
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

4.  Oxidized low-density lipoprotein induced mouse hippocampal HT-22 cell damage via promoting the shift from autophagy to apoptosis.

Authors:  Hong-Feng Gu; Hai-Zhe Li; Xue-Jiao Xie; Ya-Ling Tang; Xiao-Qing Tang; Ya-Xiong Nie; Duan-Fang Liao
Journal:  CNS Neurosci Ther       Date:  2017-02-23       Impact factor: 5.243

5.  Duloxetine Protects Human Neuroblastoma Cells from Oxidative Stress-Induced Cell Death Through Akt/Nrf-2/HO-1 Pathway.

Authors:  Daiane Fátima Engel; Jade de Oliveira; Vicente Lieberknecht; Ana Lucia Severo Rodrigues; Andreza Fabro de Bem; Nelson Horácio Gabilan
Journal:  Neurochem Res       Date:  2017-11-13       Impact factor: 3.996

Review 6.  Heartache and heartbreak--the link between depression and cardiovascular disease.

Authors:  Charles B Nemeroff; Pascal J Goldschmidt-Clermont
Journal:  Nat Rev Cardiol       Date:  2012-06-26       Impact factor: 32.419

7.  Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach.

Authors:  Michael Maes; Juliana Brum Moraes; Kamila Landucci Bonifacio; Decio Sabbatini Barbosa; Heber Odebrecht Vargas; Ana Paula Michelin; Sandra Odebrecht Vargas Nunes
Journal:  Metab Brain Dis       Date:  2021-01-07       Impact factor: 3.584

8.  In major affective disorders, early life trauma predict increased nitro-oxidative stress, lipid peroxidation and protein oxidation and recurrence of major affective disorders, suicidal behaviors and a lowered quality of life.

Authors:  Juliana Brum Moraes; Michael Maes; Chutima Roomruangwong; Kamila Landucci Bonifacio; Decio Sabbatini Barbosa; Heber Odebrecht Vargas; George Anderson; Marta Kubera; Andre F Carvalho; Sandra Odebrecht Vargas Nunes
Journal:  Metab Brain Dis       Date:  2018-03-14       Impact factor: 3.584

9.  Effects of transcranial photobiomodulation and methylene blue on biochemical and behavioral profiles in mice stress model.

Authors:  Reza Meynaghizadeh-Zargar; Saeed Sadigh-Eteghad; Gisou Mohaddes; Farzad Salehpour; Seyed Hossein Rasta
Journal:  Lasers Med Sci       Date:  2019-08-01       Impact factor: 3.161

10.  Antidepressant-like effect of celecoxib piroxicam in rat models of depression.

Authors:  Ronise M Santiago; Janaína Barbiero; Bruno J Martynhak; Suelen L Boschen; Luisa M da Silva; Maria F P Werner; Claudio Da Cunha; Roberto Andreatini; Marcelo M S Lima; Maria A B F Vital
Journal:  J Neural Transm (Vienna)       Date:  2014-01-24       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.